Targovax ASA, a clinical stage company focused on developing immuno-oncology therapies to target solid tumors, announced on Monday that Michael Bogenstaetter has been appointed as the its Chief Business Officer (CBO).
Targovax noted that Bogenstaetter will take up this role in January 2018.
The new CBO joins Targovax after 25 years’ experience in biotech and big pharma. His new company pointed out in the press release that during this time he held senior business development and strategy positions with Sanofi, Novartis and MDS.
Øystein Soug, CEO of Targovax said that Bogenstaetter’s experience will be indispensable to the company. “2018 is set to be another important year for the company, containing a number of significant milestones for our pipeline of novel immuno-oncology therapies targeting treatment-resistant solid tumors,” Soug said.